IZABRIGHT-Breast01:Izalontamab Brengitecan(BMS-986507)vs Tx of Physician's Choice - Clinical Trial
¿Cuál es el Propósito de este estudio?
This study has 3 parts:
1. Screening - Lasts up to 28 days. You'll get heart tests, scans, and blood and urine tests.
2. Treatment - You'll be randomly picked to get either a new medicine (iza-bren) or a cancer medicine your doctor chooses. You'll visit the clinic 2-3 times every few weeks.
3. Follow-up - After treatment ends, you'll have:
- A safety check 30 days later
- Regular checkups every 12 weeks
- More tests like scans and heart checks
Adults with advanced solid tumors
¿Quién puede participar en el Estudio?
¿Quién puede participar en este estudio?
Adults with a kind of advanced breast cancer called Triple-Negative Breast Cancer (TNBC) can join if:
- Their cancer is confirmed and has spread or come back and can’t be removed with surgery
- Their cancer came back at least 6 months after their last treatment
- Their cancer came back 6 to 12 months after getting a special kind of treatment called anti-PD(L)1 therapy
¿Qué Implica?
¿Por qué se está llevando a cabo este estudio?
Doctors want to find out if a new medicine called iza-bren helps people with a certain kind of breast cancer called Triple-Negative Breast Cancer (TNBC) or ER-low breast cancer—especially for those who can’t get treatments like immunotherapy or hormone therapy.
Detalles del Estudio
